• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    What Happened With Conduit Pharmaceuticals (CDT) Stock Today?

    7/16/24 5:05:30 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CDT alert in real time by email

    Conduit Pharmaceuticals Inc (NASDAQ:CDT) shares traded higher by as much as 57% to $0.37 during Tuesday’s session before closing near flat after the company announced it received patent approval for its lead asset targeting autoimmune diseases.

    The company said this achievement allowed Conduit to participate in the Patent Prosecution Highway (PPH), expediting patent examination in key markets like the U.S., Europe and Japan.

    Conduit also said the patent, numbered 2022384750, enhanced the likelihood of approvals in other major jurisdictions, providing up to 20 years of protection crucial for drug products.

    Conduit’s research also identified cocrystals of AZD1656, leveraging solid-form technology to enhance patent protection and strategic value in pharmaceutical markets. CEO Dr. David Tapolczay emphasized the patent’s significance in bolstering its intellectual property portfolio and potential for future partnerships.

    Read Also: Why Air Products and Chemicals Shares Are Surging Today

    How To Buy CDT Stock

    By now you're likely curious about how to participate in the market for Conduit Pharmaceuticals — be it to purchase shares, or even attempt to bet against the company.

    Buying shares is typically done through a brokerage account. There is a list of possible trading platforms here. Many will allow a person to buy “fractional shares,” which allows ownership of portions of stock without buying an entire share. For example, some stock, such as Berkshire Hathaway or Amazon.com, can cost thousands of dollars to own just one share. However, if a person only wants to invest a fraction of that, brokerages will allow it.

    In the the case of Conduit Pharmaceuticals, which is trading at $0.31 as of publishing time, $100 would buy 322.58 shares of stock.

    If looking to bet against a company, the process is more complex. A person will need access to an options trading platform or a broker who will allow ‘going short' a share of stock by lending the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if a broker allows a person to trade options, either buy a put option or sell a call option at a strike price above where shares are currently trading — either way it allows a profit off of the share price decline.

    CDT Price Action: According to data from Benzinga Pro, Conduit Pharmaceuticals has a 52-week high of $12.89 and a 52-week low of $0.21. Shares closed out Tuesday up 4.63% at 25 cents.

    Photo: Pexels from Pixabay

    Get the next $CDT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CDT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CDT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Regan Andrew was granted 224,800 shares (SEC Form 4)

    4 - CDT Equity Inc. (0001896212) (Issuer)

    12/22/25 4:05:28 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Regan Andrew was granted 1,120,000 shares, increasing direct ownership by 2,545,455% to 1,120,044 units (SEC Form 4)

    4 - CDT Equity Inc. (0001896212) (Issuer)

    9/22/25 4:29:05 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO Bligh James was granted 480,000 shares, increasing direct ownership by 2,000,000% to 480,024 units (SEC Form 4)

    4 - CDT Equity Inc. (0001896212) (Issuer)

    9/19/25 4:46:26 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDT
    SEC Filings

    View All

    SEC Form 424B3 filed by CDT Equity Inc.

    424B3 - CDT Equity Inc. (0001896212) (Filer)

    2/10/26 4:20:12 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by CDT Equity Inc.

    EFFECT - CDT Equity Inc. (0001896212) (Filer)

    2/10/26 12:15:21 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by CDT Equity Inc.

    S-8 - CDT Equity Inc. (0001896212) (Filer)

    1/30/26 9:06:13 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CDT Engages NJS Foresight Bio-Advisory to Support Solid-Form Out-Licensing Strategy

    NAPLES, Fla. and CAMBRIDGE, United Kingdom, Jan. 02, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced that it has engaged NJS Foresight Bio-Advisory, LLC to identify, source and support the execution of out-licensing opportunities for selected assets within its solid-form patent portfolio. The engagement is intended to expand CDT's commercial reach and accelerate potential licensing and royalty-based transactions. NJS Foresight Bio-Advisory, LLC brings more than 20 years of out-licensing experience and has completed numerous successful licensing agreements across the biotechnology and pharmaceutical sectors. The firm's principal, Dr. Nicholas

    1/2/26 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CDT Equity Increases Bitcoin Holding

    NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 17, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced the acquisition of 9.25648743 Bitcoin ("BTC") for an aggregate purchase price of $1,005,000 (gross of fees), at an average acquisition price of $108,301.75 per BTC. Following this transaction, CDT's total Bitcoin holdings now stand at 17.9090111 BTC. This acquisition marks a continued execution of CDT's cryptocurrency treasury reserve strategy, aimed at diversifying the Company's balance sheet and enhancing long-term shareholder value through the prudent accumulation of digital assets. "CDT remains committed to strategically deploying capita

    10/17/25 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CDT Equity Inc. Announces Reverse Stock Split

    NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 09, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), announces that its board of directors has approved a 1-for-8 reverse stock split of the Company's common stock. The Company's stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios, at the Company's Special Meeting of Stockholders held on May 5, 2025. The directors expect that the reverse stock split will increase the amount of funds the Company might be able to raise to execute its strategy. The reverse stock split will become effective on October 10, 2025, at 5:

    10/9/25 8:00:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDT
    Leadership Updates

    Live Leadership Updates

    View All

    Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors

    Conduit Pharmaceuticals strengthens its Board of Directors with the addition of Simon Fry, a seasoned investment banking executive with over 30 years of experience in asset management, capital markets, and strategy development. NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit" or the "Company"), a multi-asset, clinical stage, disease-agnostic life science company delivering an efficient model for compound development, today announces the appointment of Simon Fry to its Board of Directors. Mr. Fry has over 30 years' experience in investment banking having held senior executive positions at various top-tier in

    11/19/24 4:30:00 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Conduit Pharmaceuticals to Join Russell 3000® Index

    SAN DIEGO and LONDON, June 13, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) (the "Company" or "Conduit"), today announced the Company is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted by FTSE Russell on Friday, May 24th, 2024. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automat

    6/13/24 8:00:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer

    Conduit also appoints prominent intellectual property attorney Jeffrey Lindeman as a Consultant Leadership additions underscore Conduit's commitment to strengthening and broadening its intellectual property portfolio through solid-form technology to maximize future value SAN DIEGO and LONDON, March 19, 2024 (GLOBE NEWSWIRE) --  Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") today announced the appointment of Dr. Joanne Holland as Chief Scientific Officer. Dr. Holland brings over 20 years of experience to the CSO role at Conduit, having amassed expertise across the entire development spectrum. This includes a deep knowledge base in ide

    3/19/24 7:00:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDT
    Financials

    Live finance-specific insights

    View All

    CDT Equity Increases Bitcoin Holding

    NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 17, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced the acquisition of 9.25648743 Bitcoin ("BTC") for an aggregate purchase price of $1,005,000 (gross of fees), at an average acquisition price of $108,301.75 per BTC. Following this transaction, CDT's total Bitcoin holdings now stand at 17.9090111 BTC. This acquisition marks a continued execution of CDT's cryptocurrency treasury reserve strategy, aimed at diversifying the Company's balance sheet and enhancing long-term shareholder value through the prudent accumulation of digital assets. "CDT remains committed to strategically deploying capita

    10/17/25 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Conduit Pharmaceuticals Files New Patents Following AI-Driven Combination Discoveries

    Includes Conduit's first composition of matter patent filing for AZD5658 and multiple new combination filings for AZD1656 and AZD5658Patents derived from AI-led analysis conducted in partnership with Sarborg Limited NAPLES, Fla. and CAMBRIDGE, United Kingdom, July 07, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit" or the "Company") today announces the filing of four new patent applications relating to its key assets AZD1656 and AZD5658, including the Company's first patent filings for AZD5658. These filings represent a significant expansion of Conduit's intellectual property portfolio, further supporting its strategy to advance and license differentiated, IP

    7/7/25 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health

    Collaboration leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks to capture commercial potential in the $15 billion animal health marketEvaluation of AZD5658 expands Conduit's glucokinase activator platform into novel veterinary applications, complementing AZD1656 developmentCost-efficient approach enhances Conduit's pipeline while preserving full ownership of intellectual property and data, maximizing shareholder valueSynergistic combination therapies under evaluation could redefine treatment standards in veterinary and human applications NAPLES, Fla. and CAMBRIDGE, United Kingdom, June 04, 2025 (GLOBE NEWS

    6/4/25 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Conduit Pharmaceuticals Inc.

    SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)

    11/6/24 6:01:49 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Conduit Pharmaceuticals Inc.

    SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)

    10/18/24 4:15:06 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Conduit Pharmaceuticals Inc.

    SC 13G - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)

    10/11/24 6:01:23 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care